Morgan Stanley initiated coverage of Sanofi with an Equal Weight rating and $55 price target. The analyst added six American depository receipts to the firm’s European Union Pharmaceuticals coverage. The stock’s fundamental views are fully aligned with those the firm has on the underlying stocks, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
- Sanofi price target raised to EUR 102 from EUR 98 at Morgan Stanley
- Regeneron, Sanofi announce U.S. FDA updated the label for Dupixent
- Sanofi price target lowered to $63 from $64 at Jefferies
- Sanofi upgraded to Buy from Neutral at UBS